A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
Public ClinicalTrials.gov record NCT06066515. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is open to adults who are at least 18 years old and have * a body mass index (BMI) of 30 kg/m² or more, or * a BMI of 27 kg/m² or more and at least one health problem related to their weight. People with type 2 diabetes cannot take part in this study. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. The results are compared between the groups to see whether the treatment works.
Study identification
- NCT ID
- NCT06066515
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 726 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 24, 2023
- Primary completion
- Dec 1, 2025
- Completion
- Feb 19, 2026
- Last update posted
- Mar 11, 2026
2023 – 2026
United States locations
- U.S. sites
- 32
- U.S. states
- 20
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| EmVenio Research-Phoenix-69743 | Phoenix | Arizona | 85032 | — |
| Encompass Clinical Research, Spring Valley | Spring Valley | California | 91978 | — |
| Diablo Clinical Research | Walnut Creek | California | 94598 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06519 | — |
| Alliance for Multispecialty Research, LLC - Doral | Doral | Florida | 33172 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| East Coast Institute for Research, LLC - Jacksonville | Jacksonville | Florida | 32216 | — |
| New Horizon Research Center-Miami-69732 | Miami | Florida | 33165 | — |
| West Orange Endocrinology | Ocoee | Florida | 34761 | — |
| East-West Medical Research | Honolulu | Hawaii | 96814 | — |
| Solaris Clinical Research | Meridian | Idaho | 83646 | — |
| Evanston Premier Healthcare Research LLC | Skokie | Illinois | 60077 | — |
| Velocity Clinical Research-Valparaiso-68883 | Valparaiso | Indiana | 46383 | — |
| Velocity Clinical Research-Sioux City-69728 | Sioux City | Iowa | 51106 | — |
| AMR Lexington | Lexington | Kentucky | 40509 | — |
| L-MARC Research Center | Louisville | Kentucky | 40213 | — |
| StudyMetrix Research, LLC | City of Saint Peters | Missouri | 63303 | — |
| Premier Research, Inc. | Trenton | New Jersey | 08611 | — |
| Velocity Clinical Research - Binghamton | Binghamton | New York | 13905 | — |
| Southgate Medical Group/ Southgate Medical Park | West Seneca | New York | 14224 | — |
| Physicians East, PA | Greenville | North Carolina | 27834 | — |
| Lucas Research, Inc. | Morehead City | North Carolina | 28557 | — |
| Accellacare-Wilmington-67123 | Wilmington | North Carolina | 28401 | — |
| Valley Weight Loss Clinic | Fargo | North Dakota | 58104 | — |
| EmVenio Research-Oklahoma City-70053 | Oklahoma City | Oklahoma | 73139 | — |
| Trial Management Associates | Myrtle Beach | South Carolina | 29572 | — |
| Texas Diabetes and Endocrinology | Austin | Texas | 78731 | — |
| Juno Research, LLC | Houston | Texas | 77040 | — |
| Diabetes & Glandular Disease Clinic, P.A. | San Antonio | Texas | 78229 | — |
| Consano Clinical Research | Shavano Park | Texas | 78231 | — |
| Manassas Clinical Research Center | Manassas | Virginia | 20110 | — |
| Rainier Clinical Research Center | Renton | Washington | 98057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.
Recently updated Obesity trials
Other public records listing Obesity. Sorted by last update posted; newest first. Not a recommendation.
- NCT07752979: Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities Recruiting
- NCT07792226: ENLIGHT Trial: ESG With Fundal Mucosal Ablation Not yet recruiting
- NCT07783802: A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event Not yet recruiting
- NCT07684144: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) Recruiting
- NCT07554638: Incretin Therapies in Obesity-related HFpEF Recruiting
- NCT05921487: Time Restricted Eating to Mitigate Obesity in Veterans With Spinal Cord Injury Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06066515, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06066515 live on ClinicalTrials.gov.